Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The treatment of squamous cell carcinoma of lung has not improved suffuciently. Nedaplatin is
a second-generation platinum compound that is more active against squamous cell carcinoma of
the lung with a response rate of 60%, issued by the finished Phase II trial in Japan.